Trials / Completed
CompletedNCT00656006
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Study of Albuferon with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3.
Detailed description
A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albuferon | |
| DRUG | Ribavirin |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2008-04-10
- Last updated
- 2013-08-02
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00656006. Inclusion in this directory is not an endorsement.